L. Litchfield

发表

Activation of the IFN Signaling Pathway is Associated with Resistance to CDK4/6 Inhibitors and Immune Checkpoint Activation in ER-Positive Breast Cancer

S. Hilsenbeck, R. Schiff, J. Reis-Filho, 2021, Clinical Cancer Research.

The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade.

E. Rasmussen, P. Iversen, M. Kalos, 2018, Cell reports.

COUP-TFII and its interacting proteins in breast cancer and endocrine resistance

L. Litchfield, 2013 .

Genomic Aberrations that Activate D-type Cyclins Are Associated with Enhanced Sensitivity to the CDK4 and CDK6 Inhibitor Abemaciclib.

C. Caldwell, P. Iversen, Jian Du, 2017, Cancer cell.

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer.

E. Winer, L. Garraway, O. Cohen, 2020, Cancer discovery.

Targeting CDK4 and 6 in Cancer Therapy: Emerging Preclinical Insights Related to Abemaciclib

S. Goel, D. Slamon, S. Wander, 2022, The oncologist.

The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors in patients with hormone receptor positive metastatic breast cancer

E. Winer, L. Garraway, O. Cohen, 2019, bioRxiv.

Multiple roles of COUP-TFII in cancer initiation and progression.

C. Klinge, L. Litchfield, 2012, Journal of molecular endocrinology.

Dehydroepiandrosterone-induces miR-21 transcription in HepG2 cells through estrogen receptor β and androgen receptor

C. Klinge, Y. Teng, R. Prough, 2014, Molecular and Cellular Endocrinology.

Metformin Targets Central Carbon Metabolism and Reveals Mitochondrial Requirements in Human Cancers.

E. Lengyel, J. Locasale, Xiaojing Liu, 2016, Cell metabolism.

Statin Therapy Is Associated with Improved Survival in Patients with Non-Serous-Papillary Epithelial Ovarian Cancer: A Retrospective Cohort Analysis

E. Lengyel, S. Yamada, K. Wroblewski, 2014, PloS one.

Molecular Pathways: Trafficking of Metabolic Resources in the Tumor Microenvironment

E. Lengyel, A. Mukherjee, H. Kenny, 2015, Clinical Cancer Research.

5-Aza-2-deoxycytidine and trichostatin A increase COUP-TFII expression in antiestrogen-resistant breast cancer cell lines.

C. Klinge, M. Ivanova, Lacey M. Litchfield, 2014, Cancer letters.

Reduced Expression of miR-200 Family Members Contributes to Antiestrogen Resistance in LY2 Human Breast Cancer Cells

C. Klinge, Penn Muluhngwi, Y. Teng, 2013, PloS one.

Combined inhibition of PIM and CDK4/6 suppresses both mTOR signaling and Rb phosphorylation and potentiates PI3K inhibition in cancer cells

J. M. Sauder, C. Mur, S. Buchanan, 2020, Oncotarget.

Identification and Characterization of Nucleolin as a COUP-TFII Coactivator of Retinoic Acid Receptor β Transcription in Breast Cancer Cells

S. Datta, W. Pierce, C. Klinge, 2012, PloS one.

Metformin inhibits ovarian cancer growth and increases sensitivity to paclitaxel in mouse models.

E. Lengyel, Yilin Zhang, A. Mukherjee, 2015, American journal of obstetrics and gynecology.

COUP-TFII inhibits NFkappaB activation in endocrine-resistant breast cancer cells

S. Datta, C. Klinge, Savitri N. Appana, 2014, Molecular and Cellular Endocrinology.

Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study

M. Goetz, M. Beeram, H. Burris, 2022, Frontiers in Oncology.

Mesothelial Cell HIF1α Expression Is Metabolically Downregulated by Metformin to Prevent Oncogenic Tumor-Stromal Crosstalk.

M. Mann, O. Fiehn, E. Lengyel, 2019, Cell reports.

β-D-glucan inhibits endocrine-resistant breast cancer cell proliferation and alters gene expression

C. Klinge, N. Al-Rayyan, Brandie N. Radde, 2014, International journal of oncology.

Dehydroepiandrosterone Activation of G-protein-coupled Estrogen Receptor Rapidly Stimulates MicroRNA-21 Transcription in Human Hepatocellular Carcinoma Cells*

C. Klinge, Y. Teng, R. Prough, 2015, The Journal of Biological Chemistry.

LBA18 Final overall survival (OS) for abemaciclib plus trastuzumab +/- fulvestrant versus trastuzumab plus chemotherapy in patients with HR+, HER2+ advanced breast cancer (monarcHER): A randomized, open-label, phase II trial

H. Denys, S. Tolaney, J. Nadal, 2022, Annals of Oncology.

Abstract PD2-06: Efficacy of abemaciclib based on genomic alterations detected in baseline circulating tumor DNA from the MONARCH 3 study of abemaciclib plus nonsteroidal aromatase inhibitor

M. Goetz, M. Campone, S. Johnston, 2020 .

Hyperglycemia-induced metabolic compensation inhibits metformin sensitivity in ovarian cancer

E. Lengyel, A. Mukherjee, V. Shridhar, 2015, Oncotarget.

Correction: Clinical Significance of PIK3CA and ESR1 Mutations in Circulating Tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib plus Fulvestrant.

Hong Wang, P. Neven, A. Llombart-Cussac, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Clinical Significance of PIK3CA and ESR1 Mutations in circulating tumor DNA: Analysis from the MONARCH 2 Study of Abemaciclib Plus Fulvestrant.

P. Neven, Hong Wang, G. Sledge, 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

Abstract PD2-09: The genomic landscape of intrinsic and acquired resistance to cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) in patients with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC)

E. Winer, L. Garraway, Pingping Mao, 2020 .

Abstract 4458: Clinical significance ofPIK3CAandESR1mutations in ctDNA and FFPE samples from the MONARCH 2 study of abemaciclib plus fulvestrant

P. Neven, G. Sledge, A. Llombart-Cussac, 2019, Clinical Research (Excluding Clinical Trials).

Acquired genomic alterations in circulating tumor DNA from patients receiving abemaciclib alone or in combination with endocrine therapy.

M. Goetz, M. Campone, S. Johnston, 2020 .

Characterizing demographics, clinical, and genomic characteristics for U.S. patients with HR+, HER2- metastatic breast cancer following progression on a CDK4 and 6 inhibitor.

F. André, Yongmei Chen, A. Aggarwal, 2021 .

Clinical and Genomic Characteristics of Patients with Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer Following Progression on Cyclin-Dependent Kinase 4 and 6 Inhibitors

Yongmei Chen, A. Aggarwal, J. Beyrer, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.

Landscape of Baseline and Acquired Genomic Alterations in Circulating Tumor DNA with Abemaciclib Alone or with Endocrine Therapy in Advanced Breast Cancer

M. Goetz, A. Llombart-Cussac, S. Hurvitz, 2023, Clinical cancer research : an official journal of the American Association for Cancer Research.